Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

被引:21
|
作者
Bastidas-Mora, Gabriela [1 ,2 ]
Bea, Silvia [1 ,2 ,3 ,4 ,5 ]
Navarro, Alba [3 ,5 ]
Gine, Eva [1 ,2 ,3 ,5 ]
Costa, Dolors [1 ,2 ,3 ,5 ]
Delgado, Julio [1 ,2 ,3 ,5 ]
Baumann, Tycho [1 ,2 ,5 ,6 ]
Magnano, Laura [1 ,2 ,3 ]
Rivas-Delgado, Alfredo [1 ,2 ,3 ]
Villamor, Neus [1 ,2 ,3 ,5 ]
Colomer, Dolors [1 ,2 ,3 ,4 ,5 ]
Lopez-Guerra, Monica [1 ,2 ,3 ,5 ]
Rozman, Maria [1 ,2 ,3 ]
Balague, Olga [1 ,2 ,3 ,5 ]
Martinez, Daniel [1 ,2 ,5 ]
Baptista, Maria Joao [7 ]
Escoda, Lourdes [8 ]
Alcoceba, Miguel [5 ,9 ]
Blanes, Margarita [10 ]
Climent, Fina [11 ]
Campo, Elias [1 ,2 ,3 ,4 ,5 ]
Wotherspoon, Andrew [12 ]
Lopez-Guillermo, Armando [1 ,2 ,3 ,4 ,5 ]
Matutes, Estella [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[2] Hosp Clin Barcelona, Hematopathol Sect, Pathol Dept, Barcelona, Spain
[3] Inst Invest Biomed August Pi i Sunyer IDIBAP, Barcelona, Spain
[4] Univ Barcelona, Barcelona, Spain
[5] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[6] Hosp 12 Octubre, Serv Hematol, Madrid, Spain
[7] Josep Carreras Leukaemia Res Inst IJC, ICO Hosp Germans Trias & Pujol, Barcelona, Spain
[8] ICO Hosp Joan XXIII, Tarragona, Spain
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, Canc Res Inst Salamanca IBMCC USAL CSIC, Salamanca, Spain
[10] Hosp Gen Univ Elda, Alicante, Spain
[11] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Barcelona, Barcelona, Spain
[12] Royal Marsden NHS Fdn Trust, London, England
关键词
splenic marginal zone lymphoma; histological transformation; complex karyotype; prognostic factors; survival; B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; VILLOUS LYMPHOCYTES; RESPONSE CRITERIA; RISK; RITUXIMAB; SURVIVAL; SPLENECTOMY; MULTICENTER; SERIES;
D O I
10.1111/bjh.17815
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0 center dot 05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4 center dot 025, P = 0 center dot 05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3 center dot 89, P < 0 center dot 001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4 center dot 92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5 center dot 294, P = 0 center dot 016) and lack of CR (HR 2 center dot 67, P < 0 center dot 001).
引用
收藏
页码:146 / 155
页数:10
相关论文
共 50 条
  • [41] HEPATITIS B INFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES, CLINICO-BIOLOGICAL EXPRESSION AND OUTCOME
    Balint-Gib, L.
    Oprisoni, A.
    Arghirescu, S.
    Isac, A.
    Jinca, C.
    Boeriu, E.
    Ordodi, V.
    Ciocarlie, O.
    Banciu, C.
    Serban, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 102 - 102
  • [42] A comparison of outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy
    Tsimberidou, A
    O'Brien, S
    Wierda, W
    Garcia-Manero, G
    Lerner, S
    Keating, M
    ANNALS OF ONCOLOGY, 2005, 16 : 124 - 124
  • [43] Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone
    Tsimberidou, Apostolia M.
    Catovsky, Daniel
    Schlette, Ellen
    O'Brien, Susan
    Wierda, William G.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Wen, Sijin
    Do, Kim-Anh
    Lerner, Susan
    Keating, Michael J.
    CANCER, 2006, 107 (01) : 125 - 135
  • [44] Clinicopathological features of CD5-positive splenic marginal zone lymphoma
    Li, Yunling
    Wang, Guannan
    Liu, Enjie
    Zhang, Dandan
    Zhang, Yanping
    Jian, Xiangyu
    Zhao, Wugan
    Li, Wencai
    JOURNAL OF CLINICAL PATHOLOGY, 2024, 77 (06) : 421 - 425
  • [45] Lymph node involvement by splenic marginal zone lymphoma: Morphological and immunohistochemical features
    Mollejo, M
    Lloret, E
    Menarguez, J
    Piris, MA
    Isaacson, PG
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (07) : 772 - 780
  • [46] Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden
    Sima, Andreea
    Hollander, Peter
    Baecklund, Eva
    Smedby, Karin E.
    Enblad, Gunilla
    Amini, Rose-Marie
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) : 568 - 579
  • [47] An insidious presentation of splenic marginal zone lymphoma
    Burcheri, Sara
    Arcaini, Luca
    Della Porta, Mattec
    Paulli, Marco
    Boveri, Emanuela
    Zibellini, Silvia
    Rumi, Elisa
    Algarotti, Alessandra
    Passamouti, Francesco
    Lazzarino, Mario
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (06): : 432 - 433
  • [48] IMMUNOPHENOTYPIC PROFILE OF SPLENIC MARGINAL ZONE LYMPHOMA
    Kakkas, I.
    Karmiris, T.
    Psarra, K.
    Kapsimali, V.
    Grigoriou, I.
    Delibasi, S.
    Gigantes, S.
    Pagoni, M.
    Tasidou, A.
    Rontogianni, D.
    Bakiri, M.
    Harhalakis, N.
    Nikiforakis, E.
    Papasteriades, C.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2008, 74B (06) : 406 - 407
  • [49] Tissue proteomics of splenic marginal zone lymphoma
    Polati, Rita
    Brandi, Jessica
    Dalai, Irene
    Zamo, Alberto
    Cecconi, Daniela
    ELECTROPHORESIS, 2015, 36 (14) : 1612 - 1621
  • [50] Rituximab monotherapy in splenic marginal zone lymphoma
    Bennett, M.
    Dave, H. P.
    Dann, E. J.
    Yegena, S.
    Chubar, E.
    Schechter, G. P.
    ANNALS OF ONCOLOGY, 2008, 19 : 228 - 228